Superior Planning, LLC’s Capricor Therapeutics CAPR Stock Holding History

Superior Planning, LLC’s Portfolio CAPR Stock Details CAPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.98K	Buy	+209	New	+$2.32K	﹤0.01%	1562

Other funds holding CAPR

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return

DG Capital Management New York $451M AUM 20.71% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

HBK Sorce Advisory Erie, Pennsylvania $5.18B AUM 12.38% 1-Year Est. Return

Superior Planning, LLC's CAPR Position: Q3 2026 in Review

Superior Planning, LLC opened a new position in Capricor Therapeutics (CAPR) in Q3 2026: 209 shares worth $1.98K. The stake represents ﹤0.01% of the portfolio and ranks #1562 among its holdings.

81 funds tracked by Wall St. Rank hold CAPR as of Q3 2026.

Superior Planning, LLC held 209 shares of Capricor Therapeutics worth $1.98K as of Q3 2026.
Capricor Therapeutics was a new Superior Planning, LLC position in Q3 2026.
Capricor Therapeutics made up ﹤0.01% of Superior Planning, LLC's portfolio in Q3 2026, its #1562 holding.
81 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q3 2026.

Based on Superior Planning, LLC's 13F filing for Q3 2026, filed 12 Nov 2026.